## Oklahoma Health Care Authority Drug Utilization Review Board

(DUR Board)

Meeting - September 8, 2010 @ 6:00 p.m.

University of Oklahoma College of Pharmacy 1110 N. Stonewall Avenue Oklahoma City, Oklahoma 73117 Room 103

#### **AGENDA**

Discussion and Action on the Following Items:

#### Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order
  - A. Roll Call Dr. Graham

#### Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum
  - A. Acknowledgment of Speakers and Agenda Items

#### Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item Approval of DUR Board Meeting Minutes See Appendix A.
  - A. July 14, 2010 DUR Minutes Vote
  - B. June 15, 2010 DUR Recommendation Memorandum
  - C. Correspondence

#### Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit See Appendix B.
  - A. Retrospective Drug Utilization Review for March 2010
  - B. Retrospective Drug Utilization Review for April 2010
  - C. Retrospective Drug Utilization Review for July 2010
  - D. Retrospective Drug Utilization Review Response for January 2010
  - E. Retrospective Drug Utilization Review Response for February 2010
  - F. Retrospective Drug Utilization Review Response for March 2010
  - G. Retrospective Drug Utilization Review Response for April 2010
  - H. Medication Coverage Activity Audit for July 2010
  - I. Medication Coverage Activity Audit for August 2010
  - J. Help Desk Activity Audit for July 2010
  - K. Help Desk Activity Audit for August 2010

#### Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

- 5. Action Item Vote to Prior Authorize Ampyra™ See Appendix C.
  - A. Product Summary
  - B. COP Recommendations

## Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

- 6. Action Item Vote to Prior Authorize Qutenza® See Appendix D.
  - A. Product Summary
  - B. COP Recommendations

#### Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman

- 7. Action Item Vote to Prior Authorize Victoza® and Bydureon® See Appendix E.
  - A. Cost Comparison
  - B. COP Recommendations

## Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

- 8. Action Item Vote to Prior Authorize Special Formulation Antibiotics See Appendix F.
  - A. COP Recommendations

### Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

- 9. Action Item Vote to Prior Authorize Anticonvulsant Medications See Appendix G.
  - A. COP Recommendations

### Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 10. Action Item Vote to Prior Authorize ProCentra® and Second Opinions Process for ADHD / Narcolepsy Category See Appendix H.
  - A. Utilization Review
  - B. COP Recommendations

## Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

- 11. Action Item Annual Review of Synagis® See Appendix I.
  - A. Current Authorization Criteria
  - B. Utilization Review
  - B. COP Recommendations

## Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

12. FDA and DEA Updates – See Appendix J.

## 13. Future Business

- A. Annual Review of Growth Hormones
- B. Annual Review of Narcotics
- C. Annual Review of ESAs
- D. New Product Reviews

# 14. Adjournment